Eli Lilly and Company (LLY) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $1126.50, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.8% away).
Eli Lilly discovers, develops, manufactures, and markets pharmaceuticals globally in a single business segment, selling in ~90 countries through wholesalers and healthcare providers. Key products span cardiometabolic (Mounjaro, Zepbound, Jardiance), oncology (Verzenio,... Read more
Hold if already holding. Not a fresh buy at $1126.50, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.8% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost earnings 0.75, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: conservative.
Recent developments
updated 2026-06-15Recent Developments — Eli Lilly and Company
Latest news
- NEWS Eli Lilly Stock Could Rise Sharply After Earnings (NYSE:LLY) - Seeking Alpha — Seeking Alpha positive
- NEWS Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings - investopedia.com — investopedia.com neutral
- NEWS Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings - Investopedia — Investopedia positive
- NEWS What triggered Eli Lilly shares' latest price pullback - Traders Union — Traders Union negative
- NEWS Eli Lilly and Company (LLY) Declined in Q1 Despite Strong Results - Yahoo Finance — Yahoo Finance neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $1126.50, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.8% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $1159.08 (+2.9%), stop $1046.68 (−7.6%), A.R:R -0.2:1. Score 6.3/10, moderate confidence.
Take-profit target: $1159.08 (+3.0% upside). Target $1159.08 (+2.9%), stop $1046.68 (−7.6%), A.R:R -0.2:1. Stop-loss: $1046.68.
Analyst target reached - limited upside remaining; Near 52-week high (4.8% away); Leverage penalty (D/E 1.4): -0.5.
Eli Lilly and Company trades at a P/E of 40.3 (forward 25.5). TrendMatrix value score: 3.3/10. Verdict: Hold.
39 analysts cover LLY with a consensus score of 4.1/5. Average price target: $1216.
What does Eli Lilly and Company do?Eli Lilly discovers, develops, manufactures, and markets pharmaceuticals globally in a single business segment, selling...
Eli Lilly discovers, develops, manufactures, and markets pharmaceuticals globally in a single business segment, selling in ~90 countries through wholesalers and healthcare providers. Key products span cardiometabolic (Mounjaro, Zepbound, Jardiance), oncology (Verzenio, Kyprolis), immunology (Taltz, Olumiant), and neuroscience; six products collectively accounted for 82% of total revenues in 2025.